A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

Johanna C. Bendell, Michael Thomas, Celine Pitou et al.|Investigational New Drugs|2019

Cited by 30